Moreover, high PDL-2 mRNA expression in renal cell carcinoma, melanoma, metastatic urothelial and NSCLC tumors, correlated with PDL-1, and high PDL-1 and PDL-2 mRNA were both independently associated with improved outcome to atezolizumab (Yearley et al., 2017). Here, PDCD1LG2 is linked to melanoma.